Chronic myeloid leukemia, pediatric
Revision as of 15:17, 6 July 2021 by Jwarner (talk | contribs) (→Nilotinib monotherapy {{#subobject:379fef|Regimen=1}})
Section editor | |
---|---|
Wayne H. Liang, MD, MS, FAMIA UAB Birmingham, AL WayneLiangMD |
This page contains studies that were specific to pediatric populations. For the more general CML page, follow this link.
6 regimens on this page
7 variants on this page
|
Guidelines
"How I Treat"
- 2019: Hijiya & Suttorp How I treat chronic myeloid leukemia in children and adolescents
Chronic phase, first-line therapy
Imatinib monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Champagne et al. 2011 (COG AAML0123) | 2002-2004 | Phase II (RT) |
Targeted therapy
- Imatinib (Gleevec) 340 mg/m2 PO once per day
28-day cycles
References
- COG AAML0123: Champagne MA, Fu CH, Chang M, Chen H, Gerbing RB, Alonzo TA, Cooley LD, Heerema NA, Oehler V, Wood C, French ME, Arceci RJ, Smith FO, Bernstein ML. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Jul 15;57(1):56-62. Epub 2011 Apr 4. link to original article link to PMC article contains protocol PubMed NCT00030394
Nilotinib monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Hijaya et al. 2019 (DIALOG) | 2013-2015 | Phase II (RT) |
Targeted therapy
- Nilotinib (Tasigna) 230 mg/m2 PO twice per day
Continued indefinitely
References
- DIALOG: Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, Kang HJ, Guinipero T, Karakas Z, Bautista F, Ducassou S, Yoo KH, Zwaan CM, Millot F, Aimone P, Allepuz A, Quenet S, Hourcade-Potelleret F, Hertle S, Sosothikul D. Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia. Blood. 2019 Dec 5;134(23):2036-2045. link to original article contains verified protocol link to PMC article PubMed NCT01844765
Chronic phase, relapsed or refractory
Dasatinib monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Gore et al. 2018 (CA180-226) | 2009-2014 | Phase II (RT) |
Targeted therapy
- Dasatinib (Sprycel) 60 mg/m2 PO once per day
Continued indefinitely
References
- CA180-226: Gore L, Kearns PR, de Martino ML, Lee, De Souza CA, Bertrand Y, Hijiya N, Stork LC, Chung NG, Cardos RC, Saikia T, Fagioli F, Seo JJ, Landman-Parker J, Lancaster D, Place AE, Rabin KR, Sacchi M, Swanink R, Zwaan CM. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. J Clin Oncol. 2018 May 1;36(13):1330-1338. Epub 2018 Mar 2. link to original article link to PMC article contains verified protocol PubMed NCT00777036
Nilotinib monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
(CAMN107A2120) | 2011-NR | Phase 1, <20 pts (RT) |
Note: there is no obvious publication of this trial.
Targeted therapy
References
- CAMN107A2120: NCT01077544